Craig Portell
University of Virginia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Craig Portell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:27 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04747236 · Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCLUniversity of Virginia · recruiting · PTCL · principal investigator
- Ph2NCT03834688 · Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgePrECOG, LLC. · completed · Mantle Cell Lymphoma · study chair
- Ph2NCT03113422 · Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line TherapyPrECOG, LLC. · completed · Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).R01FD006814 · FDA · UNIVERSITY OF VIRGINIA · fiscal years 2025 · $808,684 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:27 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 299 citationsRCR 9.2
- 268 citationsRCR 10.8
- Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.N Engl J Med · 202473 citationsRCR 8.2
- Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.J Clin Oncol · 202553 citationsRCR 11.5
- Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.Blood Adv · 202222 citationsRCR 1.6
- Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.Clin Cancer Res · 201712 citationsRCR 0.4
- Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.Blood Cancer J · 20254 citationsRCR 0.5
- An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.Clin Lymphoma Myeloma Leuk · 2026